<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/69DFA110-1D83-41FC-8E3C-3826D7EC7F0D"><gtr:id>69DFA110-1D83-41FC-8E3C-3826D7EC7F0D</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Masters</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100116"><gtr:id>F510C630-794E-4690-BD2D-2D896E9D9816</gtr:id><gtr:title>The caPITAL Prostate Cancer Research Group</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100116</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>688882</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>05425BAF-F051-4B1E-867B-CBC640637D6E</gtr:id><gtr:title>Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e01aa18e4392ae1a425346752fbc0718"><gtr:id>e01aa18e4392ae1a425346752fbc0718</gtr:id><gtr:otherNames>Brookman-Amissah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>HbMjdpuckxx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50F0FF24-B053-4F40-9C09-148067F6BD9C</gtr:id><gtr:title>Plexin-B1 mutations in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051a0c7c02d8e35ff4c96518467220b6"><gtr:id>051a0c7c02d8e35ff4c96518467220b6</gtr:id><gtr:otherNames>Wong OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>76FF337D413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAE7F045-A143-494F-86FF-3455147E8AF3</gtr:id><gtr:title>Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ad2795da47ac68f2a36df80b69f0f60"><gtr:id>6ad2795da47ac68f2a36df80b69f0f60</gtr:id><gtr:otherNames>Hastie C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>6AA7856493F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E7C0BF-EB3C-4CC0-9868-C6D93EA8F793</gtr:id><gtr:title>Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>8976DF8A20E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A88D2EA8-89EC-4A76-A1B5-E1512F3DDBDC</gtr:id><gtr:title>Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ad2795da47ac68f2a36df80b69f0f60"><gtr:id>6ad2795da47ac68f2a36df80b69f0f60</gtr:id><gtr:otherNames>Hastie C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>A1F48020071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137CC1CD-2FA1-437D-A353-8CE0744A4E6D</gtr:id><gtr:title>A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>QKBzF4rb1gf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100116</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>61645070-5FD7-4854-9441-A8EB3A8B21BA</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>7.4  Resources and infrastructure (disease management)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>